FMP

FMP

Enter

PCVX - Vaxcyte, I...

photo-url-https://images.financialmodelingprep.com/symbol/PCVX.png

Vaxcyte, Inc.

PCVX

NASDAQ

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

75.23 USD

0.86 (1.14%)

Build Up Free Cash Flow

Year

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Revenue

607.64M

892.25M

1.06B

1.31B

1.43B

1.78B

2.22B

2.76B

3.44B

4.29B

Operating Cash Flow

29.18M

-54.96M

-9.98M

299.08M

320.56M

153.13M

190.78M

237.68M

296.12M

368.92M

Cap Ex

-3.19M

-13.06M

-23.82M

-7.34M

-14.92M

-20.82M

-25.94M

-32.31M

-40.26M

-50.16M

Free Cash Flow

25.98M

-68.02M

-33.8M

291.74M

305.64M

132.31M

164.84M

205.37M

255.86M

318.76M

Wacc

-

-

-

-

-

Pv Lfcf

-

-

-

-

-

Sum Pv Lfcf

-

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep